Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
- Delta Air Lines (DAL) Raises Quarterly Dividend 14.7% to $0.2150; 1% Yield
- ICC sets July 24 vote on whether to remove chief prosecutor Karim Khan, WSJ reports
Evercore ISI Upgrades Vertex (VRTX) to Outperform
April 11, 2024 6:01 AM EDTEvercore ISI analyst Liisa Bayko upgraded Vertex (NASDAQ: VRTX) from In Line to Outperform with a price target of $438.00.
The analyst comments "In a surprise move (but makes all the sense now), VRTX is acquiring ALPN, a company focused on developing protein-based... More
